The experimental drug successfully treated 18 leukemia patients who had not responded to other treatments. Acute myelogenous leukemia, a type of blood cancer, has an average three-year life expectancy of 25%. The researchers managed to cure every third participant in clinical trials.
Revumenib is the name of a drug tested by American scientists. The results are preliminary and do not indicate a definitive cure, but those responsible for the study are optimistic. “We believe that this drug is extremely effective and we hope that it will be available to all patients who need it,” he says. Gaias Issa ao El Pais.
But the drug does not work in all cases of acute myelogenous leukemia. The researchers focused on two genetic subtypes in which the so-called “girly” protein contributes to the progression of leukemia. It is with this protein that Revumenib binds and inhibits.
Preliminary results were published on Wednesday. In the magazine Nature.
Author: morning Post
Source: CM Jornal
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.